Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
@deepbluediver Thanks, yes I’m still here, but like you I won’t be on this BB so often. A big lesson for me, but I still have other shares, so hopefully they will come good. I will leave my money in HE1, but if I see better opportunities to make some money back then I will sell some shares. Unfortunately, I liked drilling for Helium because it is more Earth friendly, so won’t be putting any money into oilers! Keep safe and I hope to see you when things are better!! 8-)
Here is the Motley Fool article. A speculative investment???
After the market’s opening bell today, Open Orphan (LSE: ORPH) stock shot up by more than 15%, although it’s eased back a bit since.
The small-cap company operates as a pharmaceutical services business and describes itself as “a rapidly growing specialist contract research organisation.” It’s also building up an orphan drug consulting service to help pharmaceutical companies commercialise their products in Europe. The firm reckons it is a “world leader” in vaccine and antiviral testing using human challenge clinical trials.
And today’s move in the stock price was driven by a news announcement. The company has signed a human challenge clinical trial contract with a “major” global pharmaceutical company worth just over £8m. The deal involves Open Orphan testing the partner company’s inhaled human rhinovirus (hRV) antiviral product aimed at treating asthma.
This antiviral study should begin during the first half of 2022. And Open Orphan expects most of the revenue from the contract to arrive in 2021 and 2022.
Executive chairman Cathal Friel said the contract adds to the firm’s “exciting” pipeline of RSV, hRV, influenza, malaria, and asthma challenge study contracts. And he reckons the pandemic has revealed decades of underinvestment in infectious diseases and respiratory products. When the pandemic arrived, he feels the world had very few infectious disease products to deal with it.
However, there’s an opportunity in that situation for companies such as Open Orphan. Friel thinks governments and pharma companies are now investing “hugely” in new infectious and respiratory disease products. He reckons the market will likely grow from the $20bn seen in 2019 to around $250bn by 2025. Friel
Thanks Deepbluediver, much appreciated. I have today bought a few more with a view to selling when the price goes up again. But when it goes up, I may then not want to sell!! It’s so hard trying to figure out the right thing to do. Fingers crossed for this drill, but they are still recovering from getting burnt!
Mr Spacetomato, you have been ace, along with Dai, Deepbluediver, Trekmadone and Joshwaa. Lots of others have also shown be great and shown that it’s just a small percentage of scum!! GLA on this second drill, onwards and downwards (the drill, not the share price!!!)
I agree Oruin, the day the RNS dropped and for quite a few days after I saw just how nasty a small percentage of the human race can be. Didn’t sell though, in fact I did do a small top up. All the gloaters and those predictors of 5p seem to have disappeared now!!
Big plan, I was pretty miffed this morning, but this is only the 1st of 3 drills, so all is not lost. What I am miffed about is the directors talk interview which in my view gave a completely false impression of where we were. I also can’t believe the number of nasty posts made today. I clearly hope it made all those tiny ducks feel like big men!!
Ceejay when you say tomorrow, do you mean the investor update today??
I get the feeling it’s only busy on this board when the negative nicks are posting. Unfortunately they have killed off any feel good spirit on here so people don’t bother with it anymore.
I was thinking about the ongoing conversation today and the thought came to me that it is good that not everyone thinks the same. If everyone thought the same there would be no ability to deal as everyone would want to buy at the same time and sell at the same time. It only works if there are people that want to buy whilst others want to sell. And this can be applied to everything in life.
Last 2 words of title of the post with no space!! 8-)
Missing bit in link is **********
Trader's Cafe with Zak Mir: DeepVerge, Eurasia, Hemogenyx, Open Orphan, Seraphim, Webis https://www.**********.co.uk/articles/trader-s-cafe-with-zak-mir-deepverge-eurasia-hemogenyx-open-orphan-seraphim-webis-4004396
Does anyone use interactive investor?? I’ve just seen they are offering £100 if you transfer to them (which I am considering as HSBC have been shocking recently). But I do t want to jump out of the frying pan into the fire!!!!
Odysseus I’ve bought stock all the way from 7p upwards, my last purchase just over a week ago. I really can’t see this going back down to 25p, but I could be wrong. What I would say is don’t tie yourself to only buying when I gets down to that price. That is a mistake that I have made quite a few times myself and have now learnt not to do it anymore. The reason…..because a share didn’t go down to a certain price that I wanted to pay, I then missed out on some huge growth. Not advise, but I believe there is going to be some huge growth very shortly on this share, don’t miss out on it for the sake of 2/3p when it could rocket!